| Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer E Kapiteijn, CAM Marijnen, ID Nagtegaal, H Putter, WH Steup, T Wiggers, ... New England Journal of Medicine 345 (9), 638-646, 2001 | 5232 | 2001 |
| Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. ID Nagtegaal, CJH van de Veld, EVD Worp, E Kapiteijn, P Quirke, ... | 1024 | 2002 |
| Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter … CAM Marijnen, E Kapiteijn, CJH Van de Velde, H Martijn, WH Steup, ... Journal of clinical oncology 20 (3), 817-825, 2002 | 733 | 2002 |
| Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands E Kapiteijn, H Putter, CJH Van De Velde British journal of surgery 89 (9), 1142-1149, 2002 | 591 | 2002 |
| Neoantigen landscape dynamics during human melanoma–T cell interactions EME Verdegaal, NFCC De Miranda, M Visser, T Harryvan, ... Nature 536 (7614), 91-95, 2016 | 471 | 2016 |
| Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response P Kvistborg, D Philips, S Kelderman, L Hageman, C Ottensmeier, ... Science translational medicine 6 (254), 254ra128-254ra128, 2014 | 420 | 2014 |
| Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo) radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized … AJ Breugom, W Van Gijn, EW Muller, Å Berglund, CBM Van den Broek, ... Annals of Oncology 26 (4), 696-701, 2015 | 391 | 2015 |
| Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma S Kelderman, B Heemskerk, H Van Tinteren, RRH Van Den Brom, ... Cancer Immunology, Immunotherapy 63, 449-458, 2014 | 363 | 2014 |
| Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial CAM Marijnen, ID Nagtegaal, E Kapiteijn, EK Kranenbarg, EM Noordijk, ... International Journal of Radiation Oncology* Biology* Physics 55 (5), 1311-1320, 2003 | 350 | 2003 |
| Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer E Kapiteijn, EK Kranenbarg, WH Steup, CW Taat, HJT Rutten, T Wiggers, ... European Journal of Surgery 165 (5), 410-420, 1999 | 350 | 1999 |
| Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer–the RAPIDO trial PJ Nilsson, B van Etten, GAP Hospers, L Påhlman, CJH van de Velde, ... BMC cancer 13, 1-9, 2013 | 341 | 2013 |
| Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma H Hoftijzer, KA Heemstra, H Morreau, MP Stokkel, EP Corssmit, ... European journal of endocrinology 161 (6), 923-931, 2009 | 289 | 2009 |
| Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicentre, randomised trial (SUMIT) RD Carvajal, S Piperno-Neumann, E Kapiteijn, PB Chapman, S Frank, ... Journal of Clinical Oncology 36 (12), 1232-1239, 2018 | 256 | 2018 |
| Mechanisms of oncogenesis in colon versus rectal cancer E Kapiteijn, GJ Liefers, LC Los, E Klein Kranenbarg, J Hermans, ... The Journal of pathology 195 (2), 171-178, 2001 | 239 | 2001 |
| Local recurrence in patients with rectal cancer diagnosed between 1988 and 1992: a population-based study in the west Netherlands E Kapiteijn, CAM Marijnen, AC Colenbrander, EK Kranenbarg, WH Steup, ... European Journal of Surgical Oncology (EJSO) 24 (6), 528-535, 1998 | 239 | 1998 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 226 | 2018 |
| The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs DL van der Velden, LR Hoes, H Van Der Wijngaart, ... Nature 574 (7776), 127-131, 2019 | 187 | 2019 |
| Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial TC Schneider, RM Abdulrahman, EP Corssmit, H Morreau, JWA Smit, ... European journal of endocrinology 167 (5), 643-650, 2012 | 166 | 2012 |
| Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome E Kapiteijn, A Brand, J Kroep, H Gelderblom Annals of Oncology 18 (10), 1745-1747, 2007 | 152 | 2007 |
| Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma MW Rohaan, TH Borch, JH Van Den Berg, Ö Met, R Kessels, ... New England journal of medicine 387 (23), 2113-2125, 2022 | 147 | 2022 |
